Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,496,877
  • Shares Outstanding, K 62,292
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -180 M
  • EBITDA $ -167 M
  • 60-Month Beta 0.66
  • Price/Sales 82.59
  • Price/Cash Flow N/A
  • Price/Book 5.87

Options Overview Details

View History
  • Implied Volatility 226.52% (-17.94%)
  • Historical Volatility 88.02%
  • IV Percentile 92%
  • IV Rank 69.07%
  • IV High 302.43% on 02/17/26
  • IV Low 56.99% on 03/10/25
  • Expected Move (DTE 23) 11.05 (44.43%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 6,123
  • Volume Avg (30-Day) 6,638
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 176,581
  • Open Int (30-Day) 162,553
  • Expected Range 13.82 to 35.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.93
  • Number of Estimates 5
  • High Estimate -0.75
  • Low Estimate -1.05
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +38.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.17 +23.30%
on 02/13/26
28.48 -12.68%
on 02/03/26
-0.21 (-0.84%)
since 01/23/26
3-Month
19.29 +28.93%
on 12/15/25
28.77 -13.56%
on 01/09/26
-3.09 (-11.05%)
since 11/25/25
52-Week
7.76 +220.49%
on 04/09/25
71.50 -65.22%
on 10/28/25
+13.88 (+126.30%)
since 02/25/25

Most Recent Stories

More News
QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

If you have suffered a loss on your uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com...

QURE : 24.87 (+3.50%)
Contact Levi & Korsinsky by April 13, 2026 Deadline to Join Class Action Against uniQure N.V.(QURE)

NEW YORK , Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

QURE : 24.87 (+3.50%)
QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

QURE : 24.87 (+3.50%)
The Gross Law Firm Reminds uniQure Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026 - QURE

NEW YORK , Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).

QURE : 24.87 (+3.50%)
NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline

PHILADELPHIA , Feb. 23, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE)...

QURE : 24.87 (+3.50%)
uniQure to Announce 2025 Financial Results

LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...

QURE : 24.87 (+3.50%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure"...

QURE : 24.87 (+3.50%)
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

LOS ANGELES , Feb. 23, 2026 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against  uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations...

QURE : 24.87 (+3.50%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , Feb. 23, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE)...

QURE : 24.87 (+3.50%)
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

NEW ORLEANS , Feb. 20, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications...

QURE : 24.87 (+3.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 27.77
2nd Resistance Point 26.45
1st Resistance Point 25.66
Last Price 24.87
1st Support Level 23.55
2nd Support Level 22.23
3rd Support Level 21.44

See More

52-Week High 71.50
Fibonacci 61.8% 47.15
Fibonacci 50% 39.63
Fibonacci 38.2% 32.11
Last Price 24.87
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar